CLINICAL UTILITY GENE CARD

Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies

Tim Ripperger^{*,1}, Kiran Tawana², Christian Kratz³, Brigitte Schlegelberger¹, Jude Fitzgibbon² and Doris Steinemann¹

European Journal of Human Genetics (2016) 24, doi:10.1038/ejhg.2015.278; published online 27 January 2016

1. DISEASE CHARACTERISTICS

1.1 Name of the disease (synonyms)

Familial platelet disorder with associated myeloid malignancies, FPDMM.

Alternative names

Familial platelet syndrome with associated myeloid malignancies.

Aspirin-like platelet disorder.

Familial thrombocytopenia with propensity to acute myeloid leukaemia.

FPD/AML syndrome.

FPS/AML syndrome.

1.2 OMIM# of the disease

601399.

1.3 Name of the analysed genes or DNA/chromosome segments

RUNX1, RUNT-related transcription factor 1.

Alternative titles; symbols

AML1, acute myeloid leukaemia 1 gene.

CBFA2, core-binding factor, RUNT-domain, alpha subunit 2.

PEBP2AB, PEBP2-Alpha-B.

1.4 OMIM# of the gene(s)

151385.

1.5 Mutational spectrum

Point mutations, intragenic deletions, and large deletions affecting 21q22.

1.6 Analytical methods

Sequencing; array-based comparative genomic hybridisation (aCGH), if available custom-made arrays with high-resolution of *RUNX1* including non-coding regions; multiplex ligation-dependent probe amplification (MLPA); in case of large genomic aberrations, cytogenetic investigations and fluorescence *in situ* hybridisation (FISH) using *RUNX1*-specific probes.

1.7 Analytical validation

Confirmation of identified sequence variants in an independent biological sample of the index case or an affected relative. In case of intragenic deletions, an independent technique or probes should be used for confirmation purposes, for example, breakpoint spanning long-distance PCR; MLPA following aCGH or vice versa.

Due to known somatic sequence variants acquired during leukaemogenesis, DNA of non-haematopoietic origin needs to be investigated to prove the constitutional origin of sequence variants in leukaemia patients.

1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report)

<1 in 1 000 000 (approximate), there are no available data on the incidence of FPDMM.

1.9 Diagnostic setting

	Yes	No
A. (Differential) diagnostics	☒	☐
B. Predictive testing	☒	☐
C. Risk assessment in relatives	☒	☐
D. Prenatal	☒	☐

Comment: Familial platelet disorder with associated myeloid malignancies (FPDMM) is a rare autosomal dominant inherited disease exhibiting incomplete penetrance and variable intra and interfamilial expressivity. Patients typically present with mild-moderate thrombocytopenia which often coincides with a bleeding history due to impaired platelet aggregation. However, some patients have asymptomatic thrombocytopenia. Overt leukaemia, which is mainly of myeloid origin, can arise from early childhood to late adulthood. Clinically, some families present with familial leukaemia rather than familial platelet disorder. However, there are obligate adult carriers displaying neither thrombocytopenia nor leukaemia.^{1,2}

Heterozygous constitutional disease-causing genetic variants of *RUNX1* or larger deletions affecting its locus in the long arm of

¹Institute of Human Genetics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; ²Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK; ³Department of Paediatric Haematology & Oncology, Hannover Medical School, Hannover, Germany

*Correspondence: Dr T Ripperger, Institute of Human Genetics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Tel: +49 511 532 9231; Fax: +49 511 532 4521; E-mail: ripperger.tim@mh-hannover.de

Received 31 July 2015; revised 18 November 2015; accepted 8 December 2015; published online 27 January 2016

chromosome 21 are the only known causes of FPDMM. Point mutations are mainly located in the N-terminal conserved Runt homology domain (RHD), and lead to haploinsufficiency and/or dominant negative effects. Leukaemogenesis requiring secondary genetic aberrations co-occurs with somatic variants affecting the second *RUNX1* allele.^{3–9}

FPDMM can be part of a contiguous gene syndrome with thrombocytopenia, dysmorphisms, mental retardation, and increased risk of leukaemia due to genomic deletions affecting large proportions of the long arm of chromosome 21.^{10,11}

There is no publicly available *RUNX1*-specific database of known pathogenic variants. However, FPDMM-associated variants previously reported are, for example, listed in the Human Gene Mutation Database (HGMD, <http://www.hgmd.cf.ac.uk/ac/index.php>, 17 November 2015) and the ClinVar database (<http://www.ncbi.nlm.nih.gov/clinvar/>, 17 November 2015).

2. TEST CHARACTERISTICS

	Genotype or disease		A: True positives	C: False negative
	Present	Absent	B: False positives	D: True negative
Test				
Positive	A	B	Sensitivity:	$A/(A+C)$
			Specificity:	$D/(D+B)$
Negative	C	D	Positive predictive value:	$A/(A+B)$
			Negative predictive value:	$D/(C+D)$

2.1 Analytical sensitivity

(proportion of positive tests if the genotype is present)

If sequencing is complemented by investigations allowing the detection of large deletions, examples by custom-made CGH arrays or MLPA, analytical sensitivity will be above 95%. Causative genetic variants in non-coding regions, for example, in introns or regulatory elements in the non-transcribed region, which are not covered by sequencing, will be missed. In addition, causative genetic variants might be missed due to allelic dropout caused, for example, by single nucleotide polymorphisms or variants within primer binding sites.

2.2 Analytical specificity

(proportion of negative tests if the genotype is not present)

In the absence of genetic variants and by performing appropriate analytical validation, the probability of negative test results is close to 100%.

2.3 Clinical sensitivity

(proportion of positive tests if the disease is present)

The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Due to the broad clinical spectrum that includes clinically healthy carriers, patients with bleeding histories, and individuals with early onset familial leukaemia, the clinical sensitivity is variable and depends on the past medical history of the index case, the expressivity of his/her disease and the family history.

2.4 Clinical specificity

(proportion of negative tests if the disease is not present)

The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.

Due to the incomplete penetrance and the chance to detect variants of unknown significance (VUS), one can expect a clinical sensitivity above 95%. Detection of VUS may hamper final conclusions.

Please note that in the context of familial leukaemia, constitutive disease-causing genetic variants in other genes need to be considered, for example, *CEBPA*, *GATA2*, *DDX41* and *ETV6*. In families with thrombocytopenia and leukaemia, *ETV6*, which is also associated with thrombocytopenia (OMIM #616216), might be of special interest.

2.5 Positive clinical predictive value

(lifetime risk to develop the disease if the test is positive)

Data allowing an estimation of the penetrance of platelet disorder are not available. However, the lifetime risk of developing leukaemia is estimated to be 30–40%.

2.6 Negative clinical predictive value

(probability not to develop the disease if the test is negative)

Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.

Index case in that family had been tested:

If the index case of the family carries a disease-causing *RUNX1* gene variant and predictive testing including appropriate analytical validation was negative in a relative, the likelihood of FPDMM is close to 0%. Regarding known allelic heterogeneity and potential locus heterogeneity in FPDMM, there remains a theoretical chance to develop the disease due to *de novo* mutations, the presence of more than one causative genetic variant of *RUNX1* in a family or the presence of causative genetic variants in other genes associated with platelet disorders or familial leukaemia.

Index case in that family had not been tested:

If no causative genetic variant is known in the index case, it is not recommended to test non-affected relatives.

3. CLINICAL UTILITY

3.1 (Differential) diagnostics: The tested person is clinically affected
(To be answered if in 1.9 'A' was marked)

3.1.1 Can a diagnosis be made other than through a genetic test?

No	☒ (continue with 3.1.4)	
Yes	☐	
	Clinically	☐
	Imaging	☐
	Endoscopy	☐
	Biochemistry	☐
	Electrophysiology	☐
	Other (please describe)	

3.1.2 Describe the burden of alternative diagnostic methods to the patient

Not applicable.

3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?

Not applicable.

3.1.4 Will disease management be influenced by the result of a genetic test?

No ☐Yes ☒

Therapy (please describe)

There is no specific treatment for FPDMM patients. Hematopoietic stem cell transplantation (HSCT) in pre-leukaemic patients with FPDMM are discussed but remain debatable. There is presently no general consensus to perform HSCT due to transplantation-associated risks, including transplantation-associated mortality, and incomplete penetrance seen in FPDMM. Recent experimental investigations using targeted gene correction for *RUNX1* may imply possible future potential for targeted therapies, however, the biosafety of such approaches as well as the ability to establish long term repopulating hematopoietic stem cells presently are unclear.^{12,13}

Prognosis (please describe)

Unknown, depending on disease manifestation and response to therapy.

Management (please describe)

If a disease-causing genetic variant is known in the family, haematopoietic stem cell transplantation using an HLA-matched relative also carrying the mutation has to be prevented.² Especially in families with high penetrance regarding leukaemia, regular clinical examinations, differential blood cell counts and annual bone marrow aspirates with morphological, cytogenetic and molecular genetic investigations to detect early signs of leukaemic initiation should be discussed with affected individuals. Patients with FPDMM, their families and their responsible physicians should be familiar with suspicious clinical symptoms of developing leukaemia.

3.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history

(To be answered if in 1.9 'B' was marked)

3.2.1 Will the result of a genetic test influence lifestyle and prevention?

If the test result is **positive** (please describe):

Yes. Due to the present risk of developing thrombocytopenia and/or leukaemia, biannual/annual clinical evaluation including a differential blood cell count should be offered. Responsible physicians should be informed to allow prompt investigations in case of suspicious symptoms. However, there is no general consensus statement on preventive measures and the necessity of routine bone marrow investigations for surveillance. In families with frequent and childhood onset of leukaemia, regular bone marrow aspirates can be discussed. In future, it might be worth evaluating whether deep or targeted-sequencing approaches can be used to detect evolving leukaemic clones^{8,9,14} and warrant haematopoietic stem cell transplantation prior to overt leukaemia.

Regarding the autosomal dominant inheritance, lifestyle and family planning might be affected by positive test results. Predictive genetic testing can only be offered after genetic counselling. Since there is no general consensus on the surveillance of individuals at risk, predictive testing of minors is debatable, but is obligate, if minors are potential-matched stem cell donors for affected relatives.

If the test result is **negative** (please describe):

Yes. Relief of the familial risk for the counsellee and his/her offspring. There is no need for routine investigations.

3.2.2 Which options in view of lifestyle and prevention does a person at risk have if no genetic test has been done (please describe)?

Even though there is no general statement on appropriate surveillance, annual clinical examinations can be offered to relatives at risk and responsible physicians should be informed about their risk of developing thrombocytopenia/thrombocyte malfunction and leukaemia.¹⁵

3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.9 'C' was marked)

3.3.1 Does the result of a genetic test resolve the genetic situation in that family?

Yes. If a causative genetic variant is identified in an index patient, FPDMM can be diagnosed, and predictive testing following genetic counselling can be offered to all family members.

3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?

Yes. If no causative genetic variant is identified, it is not worth screening unaffected family members for disease-causing *RUNX1* variants. If a causative genetic variant is identified, by direct testing of the identified familial gene variant, surveillance can be restricted to relatives carrying the causative gene variant; regarding stem cell transplantation, healthy relatives carrying the familial mutation need no evaluation as potential stem cell donors.

3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?

Yes. Predictive genetic analyses can be offered following genetic counselling. However, regarding predictive testing of minors, the legal framework may vary from nation to nation and it should be considered that there is no expert statement on recommended surveillance measures.

3.4 Prenatal diagnosis

(To be answered if in 1.9 'D' was marked)

3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis?

Technically, prenatal or preimplantational genetic analyses are feasible, if the causative genetic alteration is known. However, the legal framework needs to be considered and may differ in various countries.

4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING

Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)

Haematopoietic stem cell transplants using cells of HLA-matched relatives carrying the familial gene variant need to be avoided.² In this respect, predictive testing of healthy relatives, even of minors, is indicated, although the test result might not be of immediate medical consequence, since surveillance of relatives at risk will not be recommended by all physicians.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by EuroGentest2 (Unit 2: 'Genetic testing as part of health care'), a Coordination Action under FP7 (Grant Agreement Number 261469), the European Society of Human Genetics, and by Bloodwise Programme Award UK, 14032.

- 1 Song WJ, Sullivan MG, Legare RD *et al*: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nat Genet* 1999; **23**: 166–175.
- 2 Owen CJ, Toze CL, Koochin A *et al*: Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. *Blood* 2008; **112**: 4639–4645.
- 3 Preudhomme C, Renneville A, Bourdon V *et al*: High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. *Blood* 2009; **113**: 5583–5587.
- 4 Ripperger T, Steinemann D, Göhring G *et al*: A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? *Leukemia* 2009; **23**: 1364–1366.
- 5 Béri-Dexheimer M, Latger-Cannard V, Philippe C *et al*: Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. *Eur J Hum Genet* 2008; **16**: 1014–1018.
- 6 Michaud J, Wu F, Osato M *et al*: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. *Blood* 2002; **99**: 1364–1372.
- 7 Ripperger T, Tauscher M, Ehler K *et al*: Childhood onset of leukaemia in familial platelet disorder with propensity for myeloid malignancies due to an intragenic RUNX1 deletion. *Haematologica* 2012; **97** (s3): S14.
- 8 Antony-Debré I, Duployez N, Bucci M *et al*: Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. *Leukemia* 2015; e-pub ahead of print 28 August 2015; doi:10.1038/leu.2015.236.
- 9 Yoshimi A, Toya T, Kawazu M *et al*: Recurrent CDC25C mutations drive malignant transformation in FPD/AML. *Nat Commun* 2014; **27**: 4770.
- 10 Shinawi M, Erez A, Shardy DL *et al*: Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. *Blood* 2008; **112**: 1042–1047.
- 11 Ripperger T, Tauscher M, Thomay K *et al*: No evidence for ITSN1 loss in a patient with mental retardation and complex chromosomal rearrangements of 21q21–21q22. *Leuk Res* 2013; **37**: 721–723.
- 12 Iizuka H, Kagoya Y, Kataoka K *et al*: Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. *Exp Hematol* 2015; **43**: 849–857.
- 13 Connelly JP, Kwon EM, Gao Y *et al*: Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. *Blood* 2014; **124**: 1926–1930.
- 14 Skokowa J, Steinemann D, Katsman-Kuipers JE *et al*: Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. *Blood* 2014; **123**: 2229–2237.
- 15 Ripperger T, Tauscher M, Haase D, Griesinger F, Schlegelberger B, Steinemann D: Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency. *Haematologica* 2011; **96**: 1892–1894.